Revelation Biosciences Unveils Positive Clinical Data for Gemini in Kidney Disease Treatment
I'm PortAI, I can summarize articles.
Revelation Biosciences Inc. announced positive clinical data for its investigational drug Gemini, aimed at treating acute kidney injury (AKI) and chronic kidney disease (CKD). The data will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego from March 29 to April 1, 2026. The presentation will highlight results from the PRIME clinical study, showing normalization of hyperinflammatory states in CKD patients and restoration of immunocompetence, presented by Robin Marsden, Senior VP of Biology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments